INT131

ID: int131

Aliases: T0903131, AMG131

Type: compound

Route/form: oral or route depends on studied product

Status: investigational

Evidence level: early human

Best data tier: early human

Support scope: review/regulatory

Source types: review

Linked sources: 2

Broad outcomes: Fat loss / metabolic health

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• selective PPAR-gamma modulator

Optimization domains

• diabetes
• insulin sensitivity
• metabolic

Research basis

• Designed to retain insulin sensitization while reducing classic TZD liabilities.
• Selective PPAR-gamma modulation is a coherent target class.

Limits, risks, and missing evidence

• Not approved; clinical development did not displace established therapies.
• PPAR-gamma biology carries fluid retention, adipogenesis, fracture, and cardiac concerns depending on ligand profile.

Risk flags

• investigational
• metabolic endocrine
• fluid retention

Linked papers, labels, and reviews

1. INT131: a selective modulator of PPAR gamma
   review / pubmed_int131_review_2009
   Selective PPAR-gamma modulator overview.
2. The development of INT131 as a selective PPAR-gamma modulator
   review / pmc_int131_development
   Development rationale and Phase 2 status at publication.